文献速递血栓与止血

艾美赛珠单抗预防重型A型血友病婴儿颅内出血的成本效果分析

Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis.
PubMed 文献 · Blood Adv · 2025-01-01

本研究采用马尔可夫队列模型,从美国社会视角评估艾美赛珠单抗预防0至1岁重型A型血友病(无FVIII抑制物)婴儿颅内出血的成本效果。低剂量方案增量成本效果比为每QALY 19 600美元(95%CI 12 000-29 000)。

要点

  • 标准剂量艾美赛珠单抗预防较标准治疗增量成本效果比为每QALY 99 900美元(95%CI 84 000-120 000)。
  • 低剂量艾美赛珠单抗预防的增量成本效果比为每QALY 19 600美元(95%CI 12 000-29 000)。
  • 在每QALY 150 000、104 000、50 000美元支付意愿阈值下,标准剂量方案具成本效果的概率分别为100%、66%、0%。

核心结论

  • 在0至1岁无FVIII抑制物的重型A型血友病婴儿中,艾美赛珠单抗预防较标准治疗(不预防)的增量成本效果比为每QALY 99 900美元(95%CI 84 000-120 000)。
  • 低剂量艾美赛珠单抗预防方案的增量成本效果比为每QALY 19 600美元(95%CI 12 000-29 000)。

研究设计与样本

  • 研究采用马尔可夫队列模型,从美国社会视角、终身时间跨度,比较艾美赛珠单抗预防与标准治疗(不预防)在0至1岁无FVIII抑制物的重型A型血友病婴儿中的成本效果。
  • 分析覆盖所有可接受的支付意愿阈值,主要结局为每质量调整生命年(QALY)的增量成本效果比(ICER,美元)。

主要发现

  • 标准剂量艾美赛珠单抗预防较标准治疗的ICER为每QALY 99 900美元(95%可信区间84 000-120 000)。
  • 低剂量艾美赛珠单抗预防情景分析的ICER为每QALY 19 600美元(95%CI 12 000-29 000)。
  • 概率敏感性分析显示,在每QALY 150 000、104 000、50 000美元支付意愿阈值下,标准剂量艾美赛珠单抗具成本效果的比例分别为10 000次蒙特卡洛迭代中的100%、66%、0%;低剂量艾美赛珠单抗在所有支付意愿阈值下均为100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intracranial hemorrhage (ICH) and resulting neurologic disability are severe complications for a subset of infants with severe hemophilia A (HA). Although prophylactic factor replacement reduces bleeding risk, it is typically delayed until after age 1 year due to risks associated with central venous access placement. Emicizumab, a subcutaneous activated factor VIII (FVIII) mimetic, has demonstrated safety and efficacy in preventing ICH in infants aged <12 months in the HAVEN 7 trial. Despite its high cost, the cost-effectiveness of emicizumab prophylaxis initiated during the first year of life for infants with severe HA is not known. We developed a Markov cohort model to compare emicizumab prophylaxis to standard care (no prophylaxis) in infants aged 0 to 1 year with severe HA without FVIII inhibitors. The analysis was conducted from a US societal perspective over a lifetime horizon across all accepted willingness-to-pay (WTP) thresholds. The primary outcome was the incremental cost-effectiveness ratio (ICER) in US dollar per quality-adjusted life-year (QALY). Emicizumab prophylaxis and standard care accrued 25.6 and 25.1 QALYs at costs of $13.12 million and $13.07 million, respectively, resulting in an ICER of $99 900 per QALY (95% credible interval [CI], 84 000-120 000). Scenario analysis examining prophylaxis with low-dose emicizumab resulted in an ICER of $19 600 per QALY (95% CI, 12 000-29 000). Probabilistic sensitivity analyses showed that standard-dose emicizumab is the cost-effective strategy in 100%, 66%, and 0% of 10 000 Monte Carlo iterations at WTP thresholds of $150 000, $104 000, and $50 000 per QALY, respectively, and in 100% across all WTP thresholds for low-dose emicizumab.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Glaeser-Khan S, Ito S, Sra M, et al. Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis. Blood Adv. 2025. PMID: 40795232. doi:10.1182/bloodadvances.2025016822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。